H. Raftopoulos
About
H. Raftopoulos is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, H. Raftopoulos has authored 18 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in H. Raftopoulos's work include Cancer Treatment and Pharmacology (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Erythropoietin and Anemia Treatment (3 papers). H. Raftopoulos is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Erythropoietin and Anemia Treatment (3 papers). H. Raftopoulos collaborates with scholars based in United States, Switzerland and France. H. Raftopoulos's co-authors include Charles A. Powell, John H. M. Austin, Maria C. Shiau, Amol Mujoomdar, Gregory D. Pearson, Matthew L. Sherman, Abderrahmane Laadem, Richard J. Gralla, Emilio Bria and Victoria Sung and has published in prestigious journals such as Journal of Clinical Oncology, Radiology and Modern Pathology.
In The Last Decade
H. Raftopoulos
18 papers receiving 412 citations
Peers
H. Raftopoulos
Susan E. Jorge Brazil
Teresa M. Hopper United States
F. Eskens Netherlands
Letizia Laera Italy
József Lövey Hungary
O. Saunders United Kingdom
T. Christopher Windham United States
Qiong Zhao China
Giovanna Speranza United States
Krzysztof Leśniewski-Kmak Poland
Citations per year, relative to H. Raftopoulos H. Raftopoulos (= 1×)
peers
Susan E. Jorge
Countries citing papers authored by H. Raftopoulos
Since
Specialization
Citations
This map shows the geographic impact of H. Raftopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Raftopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Raftopoulos more than expected).
Fields of papers citing papers by H. Raftopoulos
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by H. Raftopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Raftopoulos. The network helps show where H. Raftopoulos may publish in the future.
Co-authorship network of co-authors of H. Raftopoulos
This figure shows the co-authorship network connecting the top 25 collaborators of H. Raftopoulos. A scholar is included among the top collaborators of H. Raftopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Raftopoulos. H. Raftopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Raftopoulos, H., Abderrahmane Laadem, Paul J. Hesketh, et al.. (2015). Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Supportive Care in Cancer. 24(4). 1517–1525.
2.
Fields, Scott Z., H. Raftopoulos, Mark J. Alexander, et al.. (2012). Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opinion on Investigational Drugs. 22(1). 87–101.
3.
Bria, Emilio, Richard J. Gralla, H. Raftopoulos, et al.. (2011). Assessing two meta-analysis (MA) methods: Individual patient data-based (IPD) versus literature-based abstracted data (AD) in 10 MA including 37,002 patients (pts)—Are there differences of concern?. Journal of Clinical Oncology. 29(15_suppl). 6054–6054.
4.
Raftopoulos, H., et al.. (2011). A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy.. Journal of Clinical Oncology. 29(15_suppl). TPS235–TPS235.
5.
Raftopoulos, H., et al.. (2010). What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development.. Journal of Clinical Oncology. 28(15_suppl). 9093–9093.
6.
Swami, Umang, Daniel P. Petrylak, H. Raftopoulos, et al.. (2010). Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2589–2589.
7.
Gralla, Richard J., et al.. (2009). Determining the preferred dose of the serotonin antagonist (5-HT3) palonosetron: Results of an individual patient data meta-analysis (MA) of 1,947 patients in all randomized double blinded (RDB) trials. Journal of Clinical Oncology. 27(15_suppl). e20512–e20512.
8.
Gralla, Richard J., H. Raftopoulos, Emilio Bria, & Paul J. Hesketh. (2008). Cisplatin in non-small cell lung cancer (NSCLC)—Reducing the most prominent toxicity, emesis: Results of a meta-analysis with 1527 patients in randomized clinical trials (RCTs) testing the addition of an NK1 antagonist. Journal of Clinical Oncology. 26(15_suppl). 8064–8064.
9.
Marinis, Filippo de, H. Raftopoulos, Emilio Bria, et al.. (2008). Should 3-weekly docetaxel (3WD) remain the standard for second-line therapy of advanced non-small-cell lung cancer (A-NSCLC)? Meta-analysis of 7 randomized clinical trials (RCTs) with 3WD comparator arms. Journal of Clinical Oncology. 26(15_suppl). 8087–8087.
10.
Ramanathan, Ramesh K., Joel Picus, H. Raftopoulos, et al.. (2007). A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 61(3). 453–458.
11.
Mujoomdar, Amol, John H. M. Austin, Charles A. Powell, et al.. (2007). Clinical Predictors of Metastatic Disease to the Brain from Non–Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node Metastases. Radiology. 242(3). 882–888.
12.
Bria, Emilio, Richard J. Gralla, H. Raftopoulos, & Diana Giannarelli. (2007). Comparing two methods of meta-analysis in clinical research - individual patient data-based (IPD) and literature-based abstracted data (AD) methods: Analyzing five oncology issues involving more than 10,000 patients in randomized clinical trials (RCTs). Journal of Clinical Oncology. 25(18_suppl). 6512–6512.
13.
Bria, Emilio, Richard J. Gralla, H. Raftopoulos, et al.. (2005). Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit. Journal of Clinical Oncology. 23(16_suppl). 7140–7140.
14.
Bria, Emilio, R. Gralla, Diana Giannarelli, et al.. (2005). O-120 Pooled-analysis of 6494 patients in 12 trials (1994–2004)receiving post-operative adjuvant chemotherapy in non-small cell lung cancer: Analyzing the magnitude of benefit in survival. Lung Cancer. 49. S42–S42.
15.
Ahmann, F. R., Stéphane Culine, K. Papadopoulos, et al.. (2005). Phase I trial of irofulven (MGI 114) plus docetaxel in advanced cancers. Journal of Clinical Oncology. 23(16_suppl). 2042–2042.
16.
Raftopoulos, H., et al.. (2004). A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). Journal of Clinical Oncology. 22(14_suppl). 4629–4629.
17.
Raftopoulos, H., B. Escudier, Primo N. Lara, et al.. (2004). A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). Journal of Clinical Oncology. 22(14_suppl). 4629–4629.
18.
Stoopler, Mark, et al.. (2003). Histologic Assessment of Non–Small Cell Lung Carcinoma after Neoadjuvant Therapy. Modern Pathology. 16(11). 1102–1108.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Susan E. Jorge Breakdown of academic impact, for papers by Teresa M. Hopper Breakdown of academic impact, for papers by F. Eskens Breakdown of academic impact, for papers by Letizia Laera Breakdown of academic impact, for papers by József Lövey Breakdown of academic impact, for papers by O. Saunders Breakdown of academic impact, for papers by T. Christopher Windham Breakdown of academic impact, for papers by Qiong Zhao Breakdown of academic impact, for papers by Giovanna Speranza Breakdown of academic impact, for papers by Krzysztof Leśniewski-Kmak